Autonomic nervous system in viral myocarditis: Pathophysiology and therapy

Current Pharmaceutical Design

Volumn 22, Issue 4, 2016, Pages 485-498

  Cheng, Zheng ^a   Li Sha, Ge ^a   Yue Chun, Li ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Adrenergic receptor; Autonomic nervous system; Cholinergic anti inflammatory pathway; Sympathetic nerve; Vagus nerve; Viral myocarditis

Indexed keywords

ADRENERGIC RECEPTOR; NORADRENALIN; BETA ADRENERGIC RECEPTOR; CHOLINERGIC RECEPTOR;

AUTONOMIC NERVOUS SYSTEM; CHOLINERGIC SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYMPATHETIC NERVE; VAGUS NERVE; VIRUS MYOCARDITIS; ANIMAL; METABOLISM; MYOCARDITIS; VIRUS DISEASES;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; HUMANS; MYOCARDITIS; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, CHOLINERGIC; VIRUS DISEASES;

EID: 84959331861     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151222160810     Document Type: Review

References (161)

1. Kearney MT, Cotton JM, Richardson PJ, Shah AM. Viral myo-carditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad Med J 2001; 77: 4-10.
2. Koopman FA, Stoof SP, Straub RH, Van Maanen MA, Vervoor-deldonk MJ, Tak PP. Restoring the balance of the autonomic nerv- ous system as an innovative approach to the treatment of rheuma- toid arthritis. Mol Med 2011; 17: 937-948.
3. ThyagaRajan S, Priyanka HP. Bidirectional communication be-tween the neuroendocrine system and the immune system: rele- vance to health and diseases. Ann Neurosci 2012; 19: 40-46.
4. Panina G, Khot UN, Nunziata E, Cody RJ, Binkley PF. Assessmentof autonomic tone over a 24-hour period in patients with conges- tive heart failure: Relation between mean heart rate and measures of heart rate variability. Am Heart J 1995; 129: 748-753.
5. Yamada Y, Kinoshita H, Kuwahara K, et al. Inhibition of N-typeCa2+ channels ameliorates an imbalance in cardiac autonomic nerve activity and prevents lethal arrhythmias in mice with heart failure. Cardiovasc Res 2014; 104: 183-193.
6. Tanaka M, Tajima S, Mizuno K, et al. Frontier studies on fatigue,autonomic nerve dysfunction, and sleep-rhythm disorder. J Physiol Sci 2015; 65(6): 483-498.
7. Sá JC, Costa EC, da Silva E, et al. Aerobic exercise improves car-diac autonomic modulation in women with polycystic ovary syn- drome. Int J Cardiol 2015 25; 202: 356-61.
8. Bahler L, Molenaars RJ, Verberne HJ, Holleman F. Role ofthe autonomic nervous system in activation of human brown adi- pose tissue: A review of the literature. Diabetes Metab 2015; pii: S1262-S3636(15)00116-0.
9. Vrijkotte TG, van den Born BJ, Hoekstra CM, et al. Car-diac Autonomic Nervous System Activation and Metabolic Profile in Young Children: The ABCD Study. PLoS One 2015; 22: 10: e0138302.
10. Chen CJ, Kumar KJ, Chen YT, et al. Effect of Hinoki and MenikiEssential Oils on Human Autonomic Nervous System Activity and Mood States. Nat Prod Commun 2015; 10: 1305-1308.
11. Yue-Chun L, Li-Sha G, Xue-Qiang G, Jia-Feng L. The mechanismof carvedilol in experimental viral myocarditis. Curr Pharm Des 2012; 18: 1620-1624.
12. Yue-chun L, Li-sha G, Jiang-hua Ren, et al. Protective effects ofcarvedilol in murine model with the coxsackievirus B3-induced vi-Current Pharmaceutical Design, 2016, Vol. 22, No. 4 495ral myocarditis. Journal of Cardiovascular Pharmacology 2008; 51: 92-98.
13. Li YC, Ge LS, Yang PL, et al. Carvedilol treatment amelioratesacute coxsackievirus B3-induced myocarditis associated with oxi- dative stress reduction. Eur J Pharmacol 2010; 640(1-3): 112-116.
14. Yue-Chun L, Teng Z, Na-Dan Z, et al. Comparison of Effects ofivabradine versus carvedilol in murine model with the Coxsackievi- rus B3-induced viral myocarditis. PloS One 2012; 7: e39394.
15. Li YC, Luo Q, Ge LS, et al. Ivabradine inhibits the production ofproinflammatory cytokines and inducible nitric oxide synthase in acute coxsackievirus B3-induced myocarditis. Biochem Biophys Res Commun 2013; 431(3): 450-455.
16. Li-Sha G, Yi-He C, Na-Dan Z, Teng Z, Yue-Chun L. Effects ofcarvedilol treatment oncardiac cAMP response element binding protein expression and phosphorylation in acute coxsackievirus B3- induced myocarditis. BMC Cardiovasc Disord 2013; 13: 100.
17. Cheng Z, Li-Sha G, Jing-Lin Z, et al. Protective role of the cho-linergic anti-inflammatory pathway in a mouse model of viral myo- carditis. PLoS One 2014; 9: e112719.
18. Kindermann I, Barth C, Mahfoud F, et al, Bohm M. Update onmyocarditis. J Am Coll Cardiol 2012; 59: 779-792.
19. Kawai C. From myocarditis to cardiomyopathy: mechanisms ofinflammation and cell death: learning from the past for the future. Circulation 1999; 99: 1091-1100.
20. Petrella J, Cohen CJ, Gaetz J, Bergelson JM. A zebrafish cox-sackievirus and adenovirus receptor homologue interacts with cox- sackie B virus and adenovirus. J Virol 2002; 76: 10503-10506.
21. Wilson FM, Miranda QR, Chason JL, Lerner AM. Residual patho-logic changes following murine coxsackie A and B myocarditis. Am J Pathol 1969; 55: 253-265.
22. Shioi T, Matsumori A, Sasayama S. Persistent expression of cyto-kine in the chronic stage of viral myocarditis in mice. Circulation 1996; 94: 2930-2937.
23. Matsumori A. Molecular and immune mechanisms in the patho-genesis of cardiomyopathy--role of viruses, cytokines, and nitric oxide. Jpn Circ J 1997; 61: 275-291.
24. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. EurHeart J 2008; 29: 2073-2082.
25. Matsumori A, Kawai C. An animal model of congestive (dilated)cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encepha- lomyocarditis virus. Circulation 1982; 66: 355-360.
26. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. In-creased circulating cytokines in patients with myocarditis and car- diomyopathy. Br Heart J 1994; 72: 561-566.
27. Tomioka N, Kishimoto C, Matsumori A, Kawai C. Effects of pred-nisolone on acute viral myocarditis in mice. J Am Coll Cardiol 1986; 7: 868-872.
28. Kishimoto C, Kuribayashi K, Masuda T, Tomioka N, Kawai C.Immunologic behavior of lymphocytes in experimental viral myo- carditis: significance of T lymphocytes in the severity of myocardi- tis and silent myocarditis in BALB/c-nu/nu mice. Circulation 1985; 71: 1247-1254.
29. Kishimoto C, Kuribayashi K, Fukuma K, et al. Immunologic identi-fication of lymphocyte subsets in experimental murine myocarditis with encephalomyocarditis virus. Different kinetics of lymphocyte subsets between the heart and the peripheral blood, and significance of Thy 1.2+ (pan T) and Lyt 1+, 23+ (immature T) subsets in the development of myocarditis. Circ Res 1987; 61: 715-725.
30. Huber SA, Lodge PA. Coxsackievirus B-3 myocarditis in Balb/cmice. Evidence for autoimmunity to myocyte antigens. Am J Pathol 1984; 116: 21-29.
31. Seko Y, Tsuchimochi H, Nakamura T, et al. Expression of majorhistocompatibility complex class I antigen in murine ventricular myocytes infected with Coxsackievirus B3. Circ Res 1990; 67: 360-367.
32. Seko Y, Yagita H, Okumura K, Yazaki Y. T-cell receptor V betagene expression in infiltrating cells in murine hearts with acute myocarditis caused by coxsackievirus B3. Circulation 1994; 89: 2170-5.
33. Seko Y, Ishiyama S, Nishikawa T, et al. Restricted usage of T cellreceptor V alpha-V beta genes in infiltrating cells in the hearts of patients with acute myocarditis and dilated cardiomyopathy. J Clin Invest 1995; 96: 1035-1041.
34. Dahlstroem AB, Zetterstroem BE. Noradrenaline Stores In NerveTerminals Of the Spleen: Changes during Hemorrhagic Shock. Sci- ence 1965; 147: 1583-1585.
35. Zetterstrom BE, Hokfelt T, Norberg KA, Olsson P. Possibilities of adirect adrenergic influence on blood elements in the dog spleen. Acta Chir Scand 1973; 139: 117-122.
36. Nance DM, Sanders VM. Autonomic innervation and regulation ofthe immune system (1987-2007). Brain Behav Immun 2007; 21: 736-745.
37. Bellinger DL, Millar BA, Perez S, et al. Sympathetic modulation ofimmunity: relevance to disease. Cell Immunol 2008; 252: 27-56.
38. Baron R, Janig W. Sympathetic and afferent neurons projecting inthe splenic nerve of the cat. Neurosci Lett 1988; 94: 109-113.
39. Meckler RL, Weaver LC. Characteristics of ongoing and reflexdischarge of single splenic and renal sympathetic postganglionic fi- bres in cats. J Physiol 1988; 396: 139-153.
40. Hori T, Katafuchi T, Take S, Shimizu N, Niijima A. The autonomicnervous system as a communication channel between the brain and the immune system. Neuroimmunomodulation 1995; 2: 203-215.
41. Katafuchi T, Ichijo T, Take S, Hori T. Hypothalamic modulation ofsplenic natural killer cell activity in rats. J Physiol 1993; 471: 209-221.
42. Katafuchi T, Take S, Hori T. Roles of sympathetic nervous systemin the suppression of cytotoxicity of splenic natural killer cells in the rat. J Physiol 1993; 465: 343-357.
43. Pongratz G, Straub RH. The sympathetic nervous response in in-flammation. Arthritis Res Ther 2014; 16: 504.
44. Spengler RN, Allen RM, Remick DG, Strieter RM, Kunkel SL.Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J Immunol 1990; 145: 1430-134.
45. Severn A, Rapson NT, Hunter CA, Liew FY. Regulation of tumornecrosis factor production by adrenaline and beta-adrenergic ago- nists. J Immunol 1992; 148: 3441-3445.
46. Szabo C, Hasko G, Zingarelli B, et al. Isoproterenol regulates tu-mour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hy- poreactivity in endotoxaemia. Immunology 1997; 90: 95-100.
47. Spengler RN, Sud R, Knight PR, Ignatowski TA. Antinociceptionmediated by alpha(2)-adrenergic activation involves increasing tu- mor necrosis factor alpha (TNFalpha) expression and restoring TNFalpha and alpha(2)-adrenergic inhibition of norepinephrine re- lease. Neuropharmacology 2007; 52: 576-589.
48. Khan MM, Sansoni P, Silverman ED, Engleman EG, Melmon KL.Beta-adrenergic receptors on human suppressor, helper, and cyto- lytic lymphocytes. Biochem Pharmacol 1986; 35: 1137-1142.
49. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympatheticnerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
50. Heijnen CJ, Rouppe van der Voort C, Wulffraat N, van der Net J,Kuis W, Kavelaars A. Functional alpha 1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthri- tis. J Neuroimmunol 1996; 71: 223-226.
51. Heijnen CJ. Receptor regulation in neuroendocrine-immune com-munication: current knowledge and future perspectives. Brain Be- hav Immunol 2007; 21: 1-8.
52. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003; 93: 896-906.
53. Wen AY, Sakamoto KM, Miller LS. The role of the transcriptionfactor CREB in immune function. J Immunol 2010; 185: 6413-6419.
54. Song SK, Karl IE, Ackerman JJ, Hotchkiss RS. Increased intracel-lular Ca2+: a critical link in the pathophysiology of sepsis? Proc Natl Acad Sci USA 1993; 90: 3933-3937.
55. Hotchkiss RS, Osborne DF, Lappas GD, Karl IE. Calcium antago-nists decrease plasma and tissue concentrations of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-1 alpha in a mouse model of endotoxin. Shock 1995; 3: 337-342.
56. Leppanen T, Tuominen RK, Moilanen E. Protein kinase C and itsinhibitors in the regulation of inflammation: inducible nitric oxide synthase as an example. Basic Clin Pharmacol Toxicol 2014; 114: 37-43.
57. Lorton D, Lubahn C, Bellinger DL. Potential use of drugs thattarget neural-immune pathways in the treatment of rheumatoid ar- thritis and other autoimmune diseases. Curr Drug Targets Inflamm Allergy 2003; 2: 1-30.Cheng et al.
58. Harle P, Mobius D, Carr DJ, Scholmerich J, Straub RH. An oppos-ing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the lo- cal lymph nodes and spleen of mice with type II collagen-induced arthritis. Arthritis Rheum 2005; 52: 1305-1313.
59. Burnstock G. Cotransmission in the autonomic nervous system.Handb Clin Neurol 2013; 117: 23-35.
60. Sung CP, Arleth AJ, Feuerstein GZ. Neuropeptide Y upregulatesthe adhesiveness of human endothelial cells for leukocytes. Circ Res 1991; 68: 314-318.
61. Straub RH, Grum F, Strauch U, et al. Anti-inflammatory role ofsympathetic nerves in chronic intestinal inflammation. Gut 2008; 57: 911-921.
62. Pongratz G, McAlees JW, Conrad DH, Erbe RS, Haas KM, SandersVM. The level of IgE produced by a B cell is regulated by norepi- nephrine in a p38 MAPK- and CD23-dependent manner. J Immunol 2006; 177: 2926-2938.
63. Chen E, Miller GE. Stress and inflammation in exacerbations ofasthma. Brain Behav Immun 2007; 21: 993-999.
64. Steinle JJ. Sympathetic neurotransmission modulates expression ofinflammatory markers in the rat retina. Exp Eye Res 2007; 84: 118-125.
65. Arnold J, Barcena de Arellano ML, et al. Imbalance between sym-pathetic and sensory innervation in peritoneal endometriosis. Brain Behav Immun 2012; 26: 132-141.
66. Manni M, Maestroni GJ. Sympathetic nervous modulation of theskin innate and adaptive immune response to peptidoglycan but not lipopolysaccharide: involvement of beta-adrenoceptors and rele- vance in inflammatory diseases. Brain Behav Immun 2008; 22: 80-88.
67. Grebe KM, Takeda K, Hickman HD, et al. Cutting edge: Sympa-thetic nervous system increases proinflammatory cytokines and ex- acerbates influenza A virus pathogenesis. J Immunol 2010; 184: 540-4.
68. Machado MP, Rocha AM, de Oliveira LF, S et al. Autonomic nerv-ous system modulation affects the inflammatory immune response in mice with acute Chagas disease. Exp Physiol 2012; 97: 1186-1202.
69. Schlereth T, Drummond PD, Birklein F. Inflammation in CRPS:role of the sympathetic supply. Auton Neurosci 2014; 182: 102-107.
70. Levick SP, Murray DB, Janicki JS, Brower GL. Sympathetic nerv-ous system modulation of inflammation and remodeling in the hy- pertensive heart. Hypertension 2010; 55: 270-276.
71. Strack I, Schulte S, Varnholt H, et al. beta-Adrenoceptor blockadein sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis. Lab Invest 2011; 91: 252-261.
72. Hermann G, Beck FM, Tovar CA, Malarkey WB, Allen C,Sheridan JF. Stress-induced changes attributable to the sympathetic nervous system during experimental influenza viral infection in DBA/2 inbred mouse strain. J Neuroimmunol 1994; 53: 173-180.
73. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimula-tion attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-462.
74. Tracey KJ. The inflammatory reflex. Nature 2002; 420: 853-9.
75. Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009; 9:418-428.
76. Tracey KJ. Physiology and immunology of the cholinergic antiin-flammatory pathway. J Clin Invest 2007; 117: 289-296.
77. Huston JM, Ochani M, Rosas-Ballina M, et al. Splenectomy inacti-vates the cholinergic antiinflammatory pathway during lethal endo- toxemia and polymicrobial sepsis. J Exp Med 2006; 203: 1623-1628.
78. Bernik TR, Friedman SG, Ochani M, et al. Cholinergic antiinflam-matory pathway inhibition of tumor necrosis factor during ischemia reperfusion. J Vasc Surg 2002; 36: 1231-1236.
79. Bernik TR, Friedman SG, Ochani M, et al. Pharmacological stimu-lation of the cholinergic antiinflammatory pathway. J Exp Med 2002; 195: 781-788.
80. Mioni C, Bazzani C, Giuliani D, et al. Activation of an efferentcholinergic pathway produces strong protection against myocardial ischemia/reperfusion injury in rats. Crit Care Med 2005; 33: 2621-2628.
81. Ustinova EE, Schultz HD. Activation of cardiac vagal afferents inischemia and reperfusion. Prostaglandins versus oxygen-derived free radicals. Circ Res 1994; 74: 904-911.
82. de Jonge WJ, van der Zanden EP, The FO, et al. Stimulation of thevagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 2005; 6: 844-851.
83. Altavilla D, Guarini S, Bitto A, et al. Activation of the cholinergicanti-inflammatory pathway reduces NF-kappab activation, blunts TNF-alpha production, and protects againts splanchic artery occlu- sion shock. Shock 2006; 25: 500-506.
84. Guarini S, Altavilla D, Cainazzo MM, et al. Efferent vagal fibrestimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock. Circulation 2003; 107: 1189-1194.
85. van Westerloo DJ, Giebelen IA, Florquin S, et al. The vagus nerveand nicotinic receptors modulate experimental pancreatitis severity in mice. Gastroenterology 2006; 130: 1822-1830.
86. Sun P, Zhou K, Wang S, et al. Involvement of MAPK/NF-kappaBsignaling in the activation of the cholinergic anti-inflammatory pathway in experimental colitis by chronic vagus nerve stimulation. PLoS One 2013; 8: e69424.
87. Zhao M, He X, Bi XY, Yu XJ, Gil Wier W, Zang WJ. Vagal stimu-lation triggers peripheral vascular protection through the choliner- gic anti-inflammatory pathway in a rat model of myocardial ische- mia/reperfusion. Basic Res Cardiol 2013; 108: 345.
88. Huston JM, Gallowitsch-Puerta M, Ochani M, et al. Transcutaneousvagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med 2007; 35: 2762-2768.
89. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptoralpha7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-388.
90. van Westerloo DJ, Giebelen IA, Florquin S, et al. The cholinergicanti-inflammatory pathway regulates the host response during sep- tic peritonitis. J Infect Dis 2005; 191: 2138-2148.
91. Park J, Kang JW, Lee SM. Activation of the cholinergic anti-inflammatory pathway by nicotine attenuates hepatic ische- mia/reperfusion injury via heme oxygenase-1 induction. Eur J Pharmacol 2013; 707: 61-70.
92. Mabley J, Gordon S, Pacher P. Nicotine exerts an anti-inflammatory effect in a murine model of acute lung injury. In- flammation 2011; 34: 231-237.
93. Saeed RW, Varma S, Peng-Nemeroff T, et al. Cholinergic stimula-tion blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med 2005; 201: 1113-1123.
94. Luyer MD, Greve JW, Hadfoune M, Jacobs JA, Dejong CH, Buur-man WA. Nutritional stimulation of cholecystokinin receptors in- hibits inflammation via the vagus nerve. J Exp Med 2005; 202: 1023-1029.
95. Galzi JL, Bertrand D, Devillers-Thiery A, Revah F, Bertrand S,Changeux JP. Functional significance of aromatic amino acids from three peptide loops of the alpha 7 neuronal nicotinic receptor site investigated by site-directed mutagenesis. FEBS Lett 1991; 294: 198-202.
96. Boyd RT. The molecular biology of neuronal nicotinic acetylcho-line receptors. Crit Rev Toxicol 1997; 27: 299-318.
97. Berg DK, Conroy WG. Nicotinic alpha 7 receptors: synaptic op-tions and downstream signaling in neurons. J Neurobiol 2002; 53: 512-523.
98. Aaronson DS, Horvath CM. A road map for those who don't knowJAK-STAT. Science 2002; 296: 1653-1655.
99. Manzini S, Pinna C, Busnelli M, et al. Beta2-adrenergic activitymodulates vascular tone regulation in lecithin: cholesterol acyl- transferase knockout mice. Vasc Pharmacol 2015; pii: S1537-S1891(15)00182-00282.
100. Lewis SR, Nicholson A, Smith AF, Alderson P. Alpha-2 adrenergic agonists for the prevention of shivering following gen- eral anaesthesia. Cochrane Database Syst Rev 2015; 8: CD011107.
101. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity anddevelopment of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999; 10: 39-49.
102. Murray PJ. The primary mechanism of the IL-10-regulated antiin-flammatory response is to selectively inhibit transcription. Proc Natl Acad Sci USA 2005; 102: 8686-8691.
103. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18: 2195-2224.
104. Perkins ND. Integrating cell-signalling pathways with NF-kappaBand IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.Current Pharmaceutical Design, 2016, Vol. 22, No. 4 497
105. Gilmore TD. Introduction to NF-kappaB: players, pathways, per-spectives. Oncogene 2006; 25: 6680-6684.
106. Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE,Grando SA. Receptor-mediated tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J 2006; 20: 2093-2101.
107. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogene-sis and promotes tumor growth and atherosclerosis. Nat Med 2001; 7: 833-839.
108. Bayir H, Yildiz I. Postoperative atrial fibrillation and dia-stolic dysfunction; the contribution of autonomic nervous sys- tem function. Br J Anaesth 2015; 115: 476-477.
109. vigelj V, inkovec M, Avbelj V, Trobec R. Simple cardiovagaland adrenergic function tests in carotid artery stenosis patients as a potential tool for determining a transient autonomic dysfunction. Clin Auton Res 2015; 25(6): 383-390.
110. Alvares GA, Quintana DS, Hickie IB, Guastella AJ. Autonomicnervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta- analysis. J Psychiatry Neurosci 2015; 40: 140217.
111. Mangileva TA. Activity of vegetative nervous system and levels ofinflammatory cytokines during glucose tolerance test in subjects with optimal and high normal blood pressure. Kardiologiia 2015; 55: 27-32.
112. Hering D, Lachowska K, Schlaich M. Role of the sympa-thetic nervous system in stress-mediated cardiovascular disease. Curr Hypertens Rep 2015; 17: 594
113. Ulucan S, Keser A, Kaya Z, Katlandur H. Epicardial fat and coro-nary atherosclerosis: the effect of autonomic nervous sys- tem function. J Cardiovasc Med (Hagerstown) 2015; 16: 650-651.
114. Koller-Strametz J, Pacher R, Frey B, Kos T, Woloszczuk W, StanekB. Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neuro- humoral variables. J Heart Lung Transplant 1998; 17: 356-362.
115. Cicoira M, Bolger AP, Doehner W, et al. High tumour necrosisfactor-alpha levels are associated with exercise intolerance and neu- rohormonal activation in chronic heart failure patients. Cytokine 2001; 15: 80-86.
116. Aronson D, Mittleman MA, Burger AJ. Interleukin-6 levels areinversely correlated with heart rate variability in patients with de- compensated heart failure. J Cardiovasc Electrophysiol 2001; 12: 294-300.
117. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S.Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997; 79: 1128-1131.
118. Jankowska EA, Ponikowski P, Piepoli MF, Banasiak W, Anker SD,Poole-Wilson PA. Autonomic imbalance and immune activation in chronic heart failure - pathophysiological links. Cardiovasc Res 2006; 70: 434-445.
119. Hua F, Harrison T, Qin C, et al. c-Fos expression in rat brain stemand spinal cord in response to activation of cardiac ischemia- sensitive afferent neurons and electrostimulatory modulation. Am J Physiol Heart Circ Physiol 2004; 287: H2728-H2738.
120. Longhurst JC, Tjen ALSC, Fu LW. Cardiac sympathetic afferentactivation provoked by myocardial ischemia and reperfusion. Mechanisms and reflexes. Ann N Y Acad Sci 2001; 940: 74-95.
121. Jardine DL, Charles CJ, Ashton RK, et al. Increased cardiac sympa-thetic nerve activity following acute myocardial infarction in a sheep model. J Physiol 2005; 565: 325-333.
122. Graham LN, Smith PA, Stoker JB, Mackintosh AF, Mary DA.Time course of sympathetic neural hyperactivity after uncompli- cated acute myocardial infarction. Circulation 2002; 106: 793-7.
123. Graham LN, Smith PA, Stoker JB, Mackintosh AF, Mary DA.Sympathetic neural hyperactivity and its normalization following unstable angina and acute myocardial infarction. Clin Sci (Lond) 2004; 106: 605-611.
124. Airaksinen KE, Ylitalo KV, Peuhkurinen KJ, Ikaheimo MJ, HuikuriHV. Heart rate variability during repeated arterial occlusion in coronary angioplasty. Am J Cardiol 1995; 75: 877-881.
125. Joho S, Asanoi H, Takagawa J, et al. Cardiac sympathetic denerva-tion modulates the sympathoexcitatory response to acute myocar- dial ischemia. J Am Coll Cardiol 2002; 39: 436-442.
126. Manfrini O, Morgagni G, Pizzi C, Fontana F, Bugiardini R.Changes in autonomic nervous system activity: spontaneous balloon-induced myocardial ischaemia. Eur Heart J 2004; 25: 1502-1508.
127. Wang W, Ma R. Cardiac sympathetic afferent reflexes in heartfailure. Heart Fail Rev 2000; 5: 57-71.
128. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neu-roendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-1729.
129. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Duci-metière P. Heart-rate profile during exercise as a predictor of sud- den death. N Engl J Med 2005; 352: 1951-1958.
130. Tepper D. Frontiers in congestive heart failure: Effect of Me-toprolol CR/XL in chronic heart failure: Metoprolol CR/XL Ran- domised Intervention Trial in Congestive Heart Failure (MERIT- HF). Congest Heart Fail 1999; 5: 184-185.
131. Saeed A, Zaib S, Ashraf S, et al. Synthesis, cholinesterase inhibi-tion and molecular modelling studies of coumarin linked thiourea derivatives. Bioorg Chem 2015; 63: 58-63.
132. Ijomone OM, Nwoha PU. Nicotine inhibits hippocampal and striatal acetylcholinesterase activities, and demonstrates dual action on adult neuronal proliferation and maturation. Pathophysiology 2015; 22(4): 231-239.
133. Tunç AT, Aynac Koyuncu E, Arslan F. Development of an acetyl-cholinesterase-choline oxidase based biosensor for acetylcholine determination. Artif Cells Nanomed Biotechnol 2015. [Epub ahead of print]
134. Yoshii K, Iikura M, Hirayama M, Toda R, Kawabata Y. Physio-logically-based pharmacokinetic and pharmacodynamic modeling for the inhibition of acetylcholinesterase by acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach. Pharm Res 2015. [Epub ahead of print]
135. Sabbah HN. Electrical vagus nerve stimulation for the treatment ofchronic heart failure. Cleve Clin J Med 2011; 78 (Suppl 1): S24-S29.
136. Ishise H, Asanoi H, Ishizaka S, et al. Time course of sympathova-gal imbalance and left ventricular dysfunction in conscious dogs with heart failure. J Appl Physiol (1985) 1998; 84: 1234-1241.
137. Binkley PF, Nunziata E, Haas GJ, Nelson SD, Cody RJ. Parasym-pathetic withdrawal is an integral component of autonomic imbal- ance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol 1991; 18: 464-472.
138. Richard C. Stress-related cardiomyopathies. Ann Intensive Care2011; 1: 39.
139. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louri-das G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009; 54: 1747-1762.
140. Gatmaitan BG, Chason JL, Lerner AM. Augmentation of the viru-lence of murine coxsackie-virus B-3 myocardiopathy by exercise. J Exp Med 1970; 131: 1121-1236.
141. Reyes MP, Thomas JA, Ho KL, Smith FE, Lerner AM. Elevatedthymocyte norepinephrine and cyclic guanosine 3', 5' monophos- phate in T-lymphocytes from exercised mice with coxsackievirus B3 myocarditis. Biochem Biophys Res Commun 1982; 109: 704-708.
142. Ilback NG, Fohlman J, Friman G. Exercise in coxsackie B3 myo-carditis: effects on heart lymphocyte subpopulations and the in- flammatory reaction. Am Heart J 1989; 117: 1298-1302.
143. Pandey AS, Sole MJ, Floras JS, et al. 727-721 The Role of Sympa-thetic Activity in Murine Myocarditis Leading to the Development of Dilated Cardiomyopathy. J Am Coll Cardiol 1995; 25: 132A- 133A.
144. Nishio R, Matsumori A, Shioi T, et al. Denopamine, a beta1-adrenergic agonist, prolongs survival in a murine model of conges-Received: October 16, 2015 Accepted: November 24, 2015Cheng et al.tive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-alpha production in the heart. J Am Coll Cardiol 1998; 32: 808-815.
145. Yuan Z, Shioji K, Kihara Y, Takenaka H, Onozawa Y, KishimotoC. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol 2004; 286: H83-H90.
146. Nishio R, Shioi T, Sasayama S, Matsumori A. Carvedilol increasesthe production of interleukin-12 and interferon-gamma and im- proves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol 2003; 41: 340-345.
147. Nishii M, Inomata T, Niwano H, et al. Beta2-Adrenergic agonistssuppress rat autoimmune myocarditis: potential role of beta2- adrenergic stimulants as new therapeutic agents for myocarditis. Circulation 2006; 114: 936-944.
148. Kodama M, Matsumoto Y, Fujiwara M. In vivo lymphocyte-mediated myocardial injuries demonstrated by adoptive transfer of experimental autoimmune myocarditis. Circulation 1992; 85: 1918-1926.
149. Futamatsu H, Suzuki J, Mizuno S, et al. Hepatocyte growth factorameliorates the progression of experimental autoimmune myocardi- tis: a potential role for induction of T helper 2 cytokines. Circ Res 2005; 96: 823-830.
150. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effectsof beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 1999; 100: 2210-2212.
151. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al. Myocardial-directed overexpression of the human beta (1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000; 32: 817-830.
152. Barth W, Deten A, Bauer M, Reinohs M, Leicht M, Zimmer HG.Differential remodeling of the left and right heart after norepineph- rine treatment in rats: studies on cytokines and collagen. J Mol Cell Cardiol 2000; 32: 273-284.
153. Pauschinger M, Rutschow S, Chandrasekharan K, et al. Carvedilolimproves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin- 1beta and MMP-8 expression and a modulated immune response. Eur J Heart Fail 2005; 7: 444-452.
154. Yuan Z, Shioji K, Nimata M, Kishimoto C. Cardioprotective effectsof carvedilol on acute autoimmune myocarditis. Mol Cell Biochem 2004; 259: 223-227.
155. Mestroni L, Krajinovic M, Severini GM, et al. Familial dilatedcardiomyopathy. Br Heart J 1994; 72: S35-S41.
156. Sole MJ, Liu P. Viral myocarditis: a paradigm for understanding thepathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol 1993; 22: 99A-105A.
157. Factor SM, Minase T, Cho S, Dominitz R, Sonnenblick EH. Mi-crovascular spasm in the cardiomyopathic Syrian hamster: a pre- ventable cause of focal myocardial necrosis. Circulation 1982; 66: 342-354.
158. Factor SM, Minase T, Cho S, Fein F, Capasso JM, Sonnenblick EH.Coronary microvascular abnormalities in the hypertensive-diabetic rat. A primary cause of cardiomyopathy? Am J Pathol 1984; 116: 9-20.
159. Silver MA, Kowalczyk D. Coronary microvascular narrowing inacute murine coxsackie B3 myocarditis. Am Heart J 1989; 118: 173-174.
160. Leib C, Goser S, Luthje D, et al. Role of the cholinergic antiin-flammatory pathway in murine autoimmune myocarditis. Circ Res 2011; 109: 130-140.
161. Yasukawa H, Yajima T, Duplain H, et al. The suppressor of cyto-kine signaling-1 (SOCS1) is a novel therapeutic target for enterovi- rus-induced cardiac injury. J Clin Invest 2003; 111: 469-478